In the fall, pending approval by the Food and Drug Administration,
researchers at UConn expect to begin a clinical trial that sequences DNA
from the tumors of 15 to 20 women with ovarian cancer, and then using
that data to create personalized vaccines for the women. According to
the release, if the vaccines prove to be safe, researchers will then
conduct a Phase II clinical trial to analyze whether they help prolong
patients’ lives.
“This has the potential to dramatically change how we
treat cancer,” Srivastava said in the newsrelease. “This research will
serve as the basis for the first ever genomics-driven personalized
medicine clinical trial in immunotherapy of ovarian cancer.”
No comments:
Post a Comment